Clinical trialPhase 1 / Phase 2Completed
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Outcome
- Results posted; no analysis attached
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 25 March 2016
- Ended
- 9 July 2018
- Enrollment
- 23 participants
- Sites
- 7
- Primary outcomes
- Number of Participants With Dose-Limiting Toxicities (DLT); Number of Participants With AEs; Objective Response Rate (ORR) in Cohort 2
- Sponsor type
- Industry
- Results posted
- 14 August 2019
- Last update
- 14 August 2019
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 14 August 2019
- DLT/MTD
- Number of Participants With Dose-Limiting Toxicities (DLT)Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 0 of 3Cohort 2 (MEDI4736 + AZD5069): 4 of 12Values: ParticipantsTime frame: Cohort 1: From time of first dose of MEDI4736 on Day 1 up to Day 28 of Cycle 1 and Cohort 2: From time of first dose of AZD5069 and MEDI4736 on Day 1 up to Day 28 of Cycle 1 or until a participant experiences a DLT, whichever occurs first.No analysis posted for this outcome (outcome 1)
- Primary outcome
- Number of Participants With AEsAny AE: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 3 of 3Any AE: Cohort 2 (MEDI4736 + AZD5069): 20 of 20Any AE causally related to treatment (CRT): Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 3 of 3Any AE causally related to treatment (CRT): Cohort 2 (MEDI4736 + AZD5069): 14 of 20Any AE of CTCAE Grade 3 or higher: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 3 of 3Any AE of CTCAE Grade 3 or higher: Cohort 2 (MEDI4736 + AZD5069): 18 of 20Any AE of CTCAE Grade 3 or higher CRT: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 3 of 3Any AE of CTCAE Grade 3 or higher CRT: Cohort 2 (MEDI4736 + AZD5069): 10 of 20Any AE leading discontinuation of study treatment: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 2 of 3Any AE leading discontinuation of study treatment: Cohort 2 (MEDI4736 + AZD5069): 3 of 20Any AE with outcome of death: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 1 of 3Any AE with outcome of death: Cohort 2 (MEDI4736 + AZD5069): 4 of 20Values: ParticipantsTime frame: From first dose of study treatment administration (Day 1) until 90 days after the last dose of IP or initiation of the first subsequent anticancer therapy (whichever occurred first), approximately 30 months.6 of 9 rows shownNo analysis posted for this outcome (outcome 2)
- ORR
- Objective Response Rate (ORR) in Cohort 2Cohort 2 (MEDI4736 + AZD5069): 5.6 (0.58 to 19.95), n = 18Values: percentage of participants, 80% Confidence IntervalTime frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 6 weeks +/-7 days for first 48 weeks, then every 12 weeks +/-7 days thereafter until confirmed objective disease progression. Up to approximately 30 months.No analysis posted for this outcome (outcome 3)
- Participants
- Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 3 started, 0 completedCohort 2 (MEDI4736 + AZD5069): 20 started, 0 completed
- Serious adverse events
- Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine): 1 of 3Cohort 2 (MEDI4736 + AZD5069): 16 of 20Participants with at least one serious adverse event, of those at risk, as posted
11 secondary outcomes, the first 8 shown
- Duration of Response (DoR) in Cohort 2
- Cohort 2 (MEDI4736 + AZD5069) 18.29 (18.29 to 18.29), n=1 [median weeks, Inter-Quartile Range]
- DCR · Disease Control Rate (DCR) in Cohort 2
- At 6 months: Cohort 2 (MEDI4736 + AZD5069) 11.1, n=18 [percentage of participants] (first of 2 rows)
- PFS · Median Progression-Free Survival (PFS) in Cohort 2
- Cohort 2 (MEDI4736 + AZD5069) 1.6 (1.29 to 1.68), n=18 [median months, 95% Confidence Interval]
- PFS · Progression-Free Survival Rate at 3 Months (PFS3) in Cohort 2
- Cohort 2 (MEDI4736 + AZD5069) 11.1 (3.91 to 22.55), n=18 [percentage of participants, 80% Confidence Interval]
- PFS · Progression-Free Survival Rate at 6 Months (PFS6) in Cohort 2
- Cohort 2 (MEDI4736 + AZD5069) 11.1 (3.91 to 22.55), n=18 [percentage of participants, 80% Confidence Interval]
- OS · Median Overall Survival (OS) in Cohort 2
- Cohort 2 (MEDI4736 + AZD5069) 2.8 (1.68 to 3.79), n=18 [median months, 95% Confidence Interval]
- OS · Overall Survival at 6 Months (OS6) in Cohort 2
- Cohort 2 (MEDI4736 + AZD5069) 22.2 (11.19 to 35.59), n=18 [percentage of participants, 80% Confidence Interval]
- OS · Overall Survival at 12 Months (OS12) in Cohort 2
- Cohort 2 (MEDI4736 + AZD5069) 14.8 (5.74 to 27.92), n=18 [percentage of participants, 80% Confidence Interval]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Detailed description public domain (ClinicalTrials.gov)
This is a Phase Ib and II open-label, multi-center study to evaluate the safety, tolerability, pharmacodynamics, and antitumor activity of MEDI4736 in combination with chemotherapy or AZD5069 in patients with pancreatic ductal adenocarcinoma (PDAC). This study will consist of 2 independent cohorts.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Dose-Limiting Toxicities (DLT) [Cohort 1: From time of first dose of MEDI4736 on Day 1 up to Day 28 of Cycle 1 and Cohort 2: From time of first dose of AZD5069 and MEDI4736 on Day 1 up to Day 28 of Cycle 1 or until a participant experiences a DLT, whichever occurs first.]. Count Of Participants, Participants. Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 0; Cohort 2 (MEDI4736 + AZD5069) (n=12): 4.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With AEs [From first dose of study treatment administration (Day 1) until 90 days after the last dose of IP or initiation of the first subsequent anticancer therapy (whichever occurred first), approximately 30 months.]. Count Of Participants, Participants. Any AE: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 3; Cohort 2 (MEDI4736 + AZD5069) (n=20): 20. Any AE causally related to treatment (CRT): Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 3; Cohort 2 (MEDI4736 + AZD5069) (n=20): 14. Any AE of CTCAE Grade 3 or higher: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 3; Cohort 2 (MEDI4736 + AZD5069) (n=20): 18. Any AE of CTCAE Grade 3 or higher CRT: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 3; Cohort 2 (MEDI4736 + AZD5069) (n=20): 10. Any AE leading discontinuation of study treatment: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 2; Cohort 2 (MEDI4736 + AZD5069) (n=20): 3. Any AE with outcome of death: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 1; Cohort 2 (MEDI4736 + AZD5069) (n=20): 4. Any AE with outcome of death CRT: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 1; Cohort 2 (MEDI4736 + AZD5069) (n=20): 0. Any SAE: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 1; Cohort 2 (MEDI4736 + AZD5069) (n=20): 16. Any SAE CRT: Cohort 1 (MEDI4736 + Nab-paclitaxel + Gemcitabine) (n=3): 1; Cohort 2 (MEDI4736 + AZD5069) (n=20): 8.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Objective Response Rate (ORR) in Cohort 2 [RECIST assessments performed at baseline (within 28 days before start of study treatment), every 6 weeks +/-7 days for first 48 weeks, then every 12 weeks +/-7 days thereafter until confirmed objective disease progression. Up to approximately 30 months.]. Number, percentage of participants (80% Confidence Interval). Cohort 2 (MEDI4736 + AZD5069) (n=18): 5.6 (0.58 to 19.95).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response (DoR) in Cohort 2 [RECIST assessments performed at baseline (within 28 days before start of study treatment), every 6 weeks +/-7 days for first 48 weeks, then every 12 weeks +/-7 days thereafter until confirmed objective disease progression. Up to approximately 30 months.]. Median, weeks (Inter-Quartile Range). Cohort 2 (MEDI4736 + AZD5069) (n=1): 18.29 (18.29 to 18.29).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Disease Control Rate (DCR) in Cohort 2 [RECIST assessments were performed at baseline (within 28 days before start of study treatment) and every 6 weeks +/- 7 days for first 48 weeks up to 6 months and 12 months]. Number, percentage of participants. At 6 months: Cohort 2 (MEDI4736 + AZD5069) (n=18): 11.1. At 12 months: Cohort 2 (MEDI4736 + AZD5069) (n=18): 5.6.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Median Progression-Free Survival (PFS) in Cohort 2 [RECIST assessments performed at baseline (within 28 days before start of study treatment), every 6 weeks +/-7 days for first 48 weeks, then every 12 weeks +/-7 days thereafter until confirmed objective disease progression. Up to approximately 30 months.]. Median, months (95% Confidence Interval). Cohort 2 (MEDI4736 + AZD5069) (n=18): 1.6 (1.29 to 1.68).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival Rate at 3 Months (PFS3) in Cohort 2 [RECIST assessments were performed at baseline (within 28 days before start of study treatment) and every 6 weeks +/- 7 days up to 3 months]. Number, percentage of participants (80% Confidence Interval). Cohort 2 (MEDI4736 + AZD5069) (n=18): 11.1 (3.91 to 22.55).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival Rate at 6 Months (PFS6) in Cohort 2 [RECIST assessments were performed at baseline (within 28 days before start of study treatment) and every 6 weeks +/- 7 days up to 6 months]. Number, percentage of participants (80% Confidence Interval). Cohort 2 (MEDI4736 + AZD5069) (n=18): 11.1 (3.91 to 22.55).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Median Overall Survival (OS) in Cohort 2 [RECIST assessments performed at baseline (within 28 days before start of study treatment), every 6 weeks +/-7 days for first 48 weeks, then every 12 weeks +/-7 days thereafter until confirmed objective disease progression. Up to approximately 30 months.]. Median, months (95% Confidence Interval). Cohort 2 (MEDI4736 + AZD5069) (n=18): 2.8 (1.68 to 3.79).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival at 6 Months (OS6) in Cohort 2 [From first dose of study treatment (Day 1) up to 6 months]. Number, percentage of participants (80% Confidence Interval). Cohort 2 (MEDI4736 + AZD5069) (n=18): 22.2 (11.19 to 35.59).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival at 12 Months (OS12) in Cohort 2 [From first dose of study treatment (Day 1) up to 12 months]. Number, percentage of participants (80% Confidence Interval). Cohort 2 (MEDI4736 + AZD5069) (n=18): 14.8 (5.74 to 27.92).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Anti-Drug Antibody (ADAs) for MEDI4736 in Cohort 2 [On Day 1 of Cycles 1, 2, 3, 4, and 7; At months 3 and 6 after last dose]. Count Of Participants, Participants. Positive at any visit: Cohort 2 (MEDI4736 + AZD5069) (n=20): 3. Both baseline and post-baseline positive: Cohort 2 (MEDI4736 + AZD5069) (n=20): 0. Only post-baseline positive: Cohort 2 (MEDI4736 + AZD5069) (n=20): 1. Only baseline positive: Cohort 2 (MEDI4736 + AZD5069) (n=20): 2. ADA persistently positive: Cohort 2 (MEDI4736 + AZD5069) (n=20): 0. ADA transiently positive: Cohort 2 (MEDI4736 + AZD5069) (n=20): 1. ADA positive participants who are NAB positive: Cohort 2 (MEDI4736 + AZD5069) (n=20): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Mean Plasma Concentrations of MEDI4736 in Cohort 2 [Predose (within 60 minutes prior to treatment with any IP) on Day 1 of Cycles 1, 2, 3, 4, and 7; and post infusion (within 10 minutes after end of MEDI4736 infusion) on Day 1 of Cycles 1 and 7]. Mean, nanograms per milliliter (Standard Deviation). Cycle 1 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 1444.730 (1010.7667). Cycle 1 Day 1: Post infusion: Cohort 2 (MEDI4736 + AZD5069) (n=20): 339342.229 (95923.6405). Cycle 2 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 56773.555 (17716.8788). Cycle 3 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 63655.840 (26425.8402). Cycle 4 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 69325.233 (22750.3387). Cycle 7 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 79687.820 (NA) [Standard deviation cannot be calculated when only one participant analyzed.]. Cycle 7 Day 1: Post infusion: Cohort 2 (MEDI4736 + AZD5069) (n=20): 435297.610 (NA) [Standard deviation cannot be calculated when only one participant analyzed.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Mean Plasma Concentrations of AZD5069 in Cohort 2 [Predose (within 60 minutes prior to treatment with any IP) on Day 1 of Cycles 1, 2, 3, 4, and 7; and postdose (within 10 minutes after end of MEDI4736 infusion) on Day 1 of Cycles 1, 2, and 7]. Mean, nanomoles per liter (Standard Deviation). Cycle 1 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 10.60 (42.933). Cycle 1 Day 1: Postdose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 2236.29 (1678.496). Cycle 2 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 1829.36 (1473.533). Cycle 2 Day 1: Postdose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 24.40 (NA) [Standard deviation cannot be calculated when only one participant analyzed.]. Cycle 3 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 502.48 (601.914). Cycle 4 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 1345.00 (1068.666). Cycle 7 Day 1: Predose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 1200.00 (NA) [Standard deviation cannot be calculated when only one participant analyzed.]. Cycle 7 Day 1: Postdose: Cohort 2 (MEDI4736 + AZD5069) (n=20): 7540.00 (NA) [Standard deviation cannot be calculated when only one participant analyzed.].